Despite the main focus of this blog being on androgenic alopecia (also known as male pattern baldness, even though females suffer from it too), I have made a number of posts about alopecia areata on here in the past year. This is largely due to all the good news that has come out this year for people suffering from alopecia areata from the great work of people such as Dr. Angela Christiano and Dr. Brett King. In my opinion, there is also a chance that these drugs may benefit people with certain types of angrogenic alopecia where there is an inflammatory (dandruff, itching, scaling) component involved too, but this is pure conjecture on my part and entirely unproven.
Dr. Christiano recently published a good video (with more of a female focus, a rarity in the hair loss research world) on alopecia areata that includes her personal experiences with the disease. The video is embedded below. She has a few interesting slides on there:
- 11:00 = I was quite surprised to read that alopecia areata affects 5.3 million people in the US, with a 1.7 percent lifetime risk.
- 11:42 = comparison with genes involved in psoriosis and vitiligo.
- 12:15 and 12:45 = most important part of the presentation related to research on Janus kinase (JAK) inhibitors such as Ruxolitinib (JAK 1,2), Tofacitinib (JAK 1,2,3), Baricitinib (JAK 1,2), VX-509 (JAK 1,2) and R348 (JAK 1,2). The last three mentioned are not yet approved, while the first two are FDA approved for certain applications and you can read about those drugs via the “Categories” section in the left hand column of this blog.
- 12:57 = Results on mice.
- 23:47 = Great results on a woman and, thereafter, on a man.